The NIFTY™ test is a highly accurate non-invasive prenatal test (NIPT) that screens for chromosomal aneuploidies, including trisomies 21, 18 and 13, from as early as week 10 of pregnancy. NIFTY™ provides a significantly stronger risk indication than traditional screening procedures. With a sensitivity rate of >99% (validated on over 112,000 pregnancies) and a false positive rate of just 0.1% for trisomies 21, 18 and 13, NIFTY™ ensures that the number of women undergoing unnecessary invasive diagnostic procedures is significantly reduced.
To date, over 2,000,000 NIFTY samples have been processed worldwide.
|Trisomies||Sex Chromosome Aneuploidies||Deletion/Duplication Syndromes||Gender Identification|
|Down Syndrome (21)||Turner Syndrome||Cri-du-chat Syndrome||Male/Female|
|Edwards Syndrome (18)||Klinefelter Syndrome||1p36|
|Patau Syndrome (13)||XXX||2q33.1|
|22||XYY||Prader-Willi/Angelman Syndrome (15q11.2)|
|16||Jacobsen Syndrome (11q23)|
|9||DiGeorge Syndrome II (10p14-p13)|
|Van der Woude Syndrome (1q32.2)|
Testing services for trisomy conditions 21, 18 and 13 are available for twin pregnancies, egg donor pregnancies and IVF pregnancies.
*NIFTY detection rate for trisomy 21, 18 and 13.
*NIFTY FP rate for trisomy 21, 18 and 13.
1) Dan S. et al, ‘Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors.’ Prenat. Diagn., 32: 1225–1232. doi: 10.1002/pd.4002
2) Double Blinded Validation Study on 3,464 NIFTY™ Blood Samples.
3) LAU T. K. et al, ‘Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center.’ Ultrasound Obstet Gynecol 2014; 43: 254–264
View all of our published reports relating to NIPT testing.
* Test accuracy figures quoted for NIFTY™ are based on findings from three separately conducted independent studies (listed above) of non-invasive prenatal testing for fetal chromosomal abnormalities by whole-genome sequencing of maternal plasma DNA. Please refer to the Clinical Data page for more information.